Ville de Bou-Ismail

HAYA Therapeutics Heart treatment startup passes Venture Kick stage 2

Vendredi, 02.02.2018

https://www.venturekick.ch/index.cfm?CFID=607566431&CFTOKEN=78223184&page=135333&article_id=3054&JumpToAnchor=fgBerichtAnker_5641&BackPage=135422

Congratulations to HAYA Therapeutics selected by the jury to receive CHF 20,000.

HAYA Therapeutics (UNIL) – bio-tech, bio-pharma:

HAYA Therapeutics is dedicated to treating heart failure through the discovery and development of innovative first-in-class RNA-based therapeutics, with a specific focus on long noncoding RNAs. The startup aims to be the first company and world leader in translating long noncoding RNA discoveries into breakthrough bench-to-bedside tools to monitor and treat heart failure patients.

-----------------------------------------------------------------000--------------------------------------------------------------

Five startup projects win the first stage of Venture Kick

https://www.ifj.ch/Five-startup-projects-win-the-first-stage-of-Venture-Kick

Fri, 06.10.2017, 14:00

Five startups instead of four won CHF 10’000 each at the first stage of Venture Kick: Kurt, KITRO, HAYA Therapeutics, vestr and FOLDAWAY. They benefit from the annual global 3 million in cash support from the program as well as hands-on execution support at the kickers camps. They are now preparing for stage two, where they might win another CHF 20’000.


HAYA Therapeutics (UNIL) – bio-tech, bio-pharma: HAYA Therapeutics is dedicated to treating heart failure through the discovery and development of innovative first-in-class RNA-based therapeutics, with a specific focus on long noncoding RNAs. The startup aims to be the first company and world leader in translating long noncoding RNA discoveries into breakthrough bench-to-bedside tools to monitor and treat heart failure patients.

-----------------------------------------------------------------000--------------------------------------------------------------